Experts Project Lower Lifelong Organ Damage Risk With Recombinant ADAMTS13 in Rare Blood Clotting Disorder
A structured expert elicitation study projects substantially lower long-term organ damage risks for congenital thrombotic thrombocytopenic purpura patients receiving recombinant ADAMTS13 prophylaxis compared with plasma-based...
















